# Septerna, Inc. (SEPN) insider trading

> In the 12 months to Nov 15, 2026, 8 SEPN insiders reported open-market sales of $80.1M across 19 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/sepn/insider-trading
Latest filing: 2026-11-13 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $80.1M | 19 filings · 8 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 17 of 19 | $16.6M of $80.1M sold (21%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Peter Kolchinsky | Director | $31.7M | — | 1 | — | 2026-08-14 |
| Rajeev M. Shah | Director | $31.7M | — | 1 | — | 2026-08-14 |
| Third Rock Ventures GP V, LP | 10% owner | $7.4M | — | 1 | 100% of sales | 2026-08-14 |
| Alan Ezekowitz | Director | $3.9M | — | 1 | 100% of sales | 2026-11-13 |
| Samira Shaikhly | Chief People Officer | $2.8M | — | 5 | 100% of sales | 2026-06-30 |
| Elizabeth Bhatt | President and COO | $1.6M | — | 5 | 100% of sales | 2026-10-19 |
| Daniel D. Long | SVP, Drug Discovery | $888.1K | — | 4 | 100% of sales | 2026-09-03 |
| TRV GP VI, LLC | 10% owner | $7.2K | — | 1 | 100% of sales | 2026-08-14 |

## Open-market trades by filing

19 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-13 | 2026-11-11 | Alan Ezekowitz | Director | Sale (10b5-1) | 81,820 | $48.09 | $3.9M | 74,415 | — |
| 2026-10-19 | 2026-10-15 | Elizabeth Bhatt | President and COO | Sale (10b5-1) | 4,000 | $37.41 | $149.6K | 177,115 | — |
| 2026-09-03 | 2026-09-01 | Daniel D. Long | SVP, Drug Discovery | Sale (10b5-1) | 3,333 | $37.83 | $126.1K | 96,412 | — |
| 2026-08-14 | 2026-08-12 | Third Rock Ventures GP V, LP | 10% owner | Sale (10b5-1) | 147,059 | $50.27 | $7.4M | 6,068,532 | — |
| 2026-08-14 | 2026-08-12 | TRV GP VI, LLC | 10% owner | Sale (10b5-1) | 141 | $51.08 | $7.2K | 6,068,391 | — |
| 2026-08-14 | 2026-08-12 | Rajeev M. Shah | Director | Sale | 746,500 | $42.50 | $31.7M | 4,777,415 | — |
| 2026-08-14 | 2026-08-12 | Peter Kolchinsky | Director | Sale | 746,500 | $42.50 | $31.7M | 725,443 | — |
| 2026-08-13 | 2026-08-11 | Elizabeth Bhatt | President and COO | Sale (10b5-1) | 25,000 | $44.00 | $1.1M | 174,209 | — |
| 2026-08-05 | 2026-08-03 | Daniel D. Long | SVP, Drug Discovery | Sale (10b5-1) | 3,334 | $34.47 | $114.9K | 98,746 | — |
| 2026-07-17 | 2026-07-15 | Elizabeth Bhatt | President and COO | Sale (10b5-1) | 4,000 | $33.99 | $136.0K | 174,209 | — |
| 2026-07-02 | 2026-07-01 | Daniel D. Long | SVP, Drug Discovery | Sale (10b5-1) | 3,333 | $34.36 | $114.5K | 97,645 | — |
| 2026-06-30 | 2026-06-29 | Samira Shaikhly | Chief People Officer | Sale (10b5-1) | 2,178 | $35.18 | $76.6K | 793 | — |
| 2026-06-24 | 2026-06-22 | Daniel D. Long | SVP, Drug Discovery | Sale (10b5-1) | 15,000 | $35.51 | $532.6K | 96,412 | — |
| 2026-06-16 | 2026-06-12 | Samira Shaikhly | Chief People Officer | Sale (10b5-1) | 6,250 | $35.08 | $219.2K | 793 | — |
| 2026-06-03 | 2026-06-01 | Samira Shaikhly | Chief People Officer | Sale (10b5-1) | 5,935 | $28.93 | $171.7K | 5,028 | — |
| 2026-05-28 | 2026-05-26 | Samira Shaikhly | Chief People Officer | Sale (10b5-1) | 11,798 | $30.06 | $354.7K | 793 | — |
| 2026-04-17 | 2026-04-15 | Elizabeth Bhatt | President and COO | Sale (10b5-1) | 4,000 | $24.34 | $97.3K | 174,209 | — |
| 2026-03-04 | 2026-03-02 | Samira Shaikhly | Chief People Officer | Sale (10b5-1) | 70,453 | $28.10 | $2.0M | 793 | — |
| 2026-02-20 | 2026-02-18 | Elizabeth Bhatt | President and COO | Sale (10b5-1) | 4,000 | $28.97 | $115.9K | 174,209 | — |

## Other insider activity (not market trades)

- Option exercises: 21 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- **Counted once**: When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.

## FAQ

### Has Septerna, Inc.'s CEO sold stock?

No. Jeffrey Finer (CEO) made no open-market sales filed as CEO in the last 12 months.

### How current is SEPN’s insider data?

These are SEPN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The SEPN Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=SEPN&filing_date.gte=2025-11-15&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Septerna, Inc. (SEPN) stock price](https://massive.com/quote/sepn.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
